A study to evaluate the safety and tolerability of AZD7442 in Chinese Adults

Trial Identifier: D8850C00008
Sponsor: AstraZeneca
NCTID:: NCT05184062
Start Date: December 2021
Primary Completion Date: August 2022
Study Completion Date: May 2023

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
English Version
Chinese Translation

Trial Locations

Country Location
CN baoding, CN, 071000
CN Beijing, CN, 100034
CN Changsha, CN, 410008
CN chongqing, CN, 400016
CN fuzhou, CN, 350005
CN Haikou, CN, 570311
CN hangzhou, CN, 310006
CN Lanzhou, CN, 730030
CN Nanchang, CN, 330006
CN shanghai, CN, 200120
CN Shanghai, CN, 200080
CN Shanghai, CN, 200040
CN shenyang, CN, 110001
CN Suzhou, CN, 215004
CN Urumqi, CN, 830054
CN Wuxi, CN, 214023
CN Xuzhou, CN, 221000